Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASH 2014

06–09 December 2014 | San Francisco, CA

ASH 2014

06–09 December 2014 | San Francisco, CA
ASH 2014: Managing diffuse large B-cell lymphoma 1:14
ASH 2014: Managing diffuse large B-cell lymphoma
Christian Gisselbrecht • 5 Dec 2014
Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia 5:41
Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
Christoph Röllig • 6 Dec 2014
Phase I study shows AG-221 induces durable remissions in IDH2-mutant acute myeloid leukaemia 7:18
Phase I study shows AG-221 induces durable remissions in IDH2-mutant acute myeloid leukaemia
Eytan Stein • 5 Dec 2014
Phase III trial shows vosaroxin improves overall survival in acute myeloid leukaemia 7:52
Phase III trial shows vosaroxin improves overall survival in acute myeloid leukaemia
Farhad Ravandi • 6 Dec 2014
Recent advances in CLL (part 3) 4:32
Recent advances in CLL (part 3)
John Gribben • 9 Dec 2014
Recent advances in CLL (part 2) 3:24
Recent advances in CLL (part 2)
John Gribben et al. • 9 Dec 2014
Recent advances in CLL (part 1) 8:42
Recent advances in CLL (part 1)
John Gribben et al. • 9 Dec 2014
Treatment of haematological malignancies with idelalisib 4:24
Treatment of haematological malignancies with idelalisib
Ian Flinn • 5 Dec 2014
Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL 1:18
Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL
Ian Flinn • 5 Dec 2014
Phase Ib shows pembrolizumab elicits complete or partial remission in Hodgkin lymphoma 5:56
Phase Ib shows pembrolizumab elicits complete or partial remission in Hodgkin lymphoma
Craig Moskowitz
Phase I study shows nivolumab is safe and tolerable for relapsed or refractory Hodgkin lymphoma 7:51
Phase I study shows nivolumab is safe and tolerable for relapsed or refractory Hodgkin lymphoma
Philippe Armand • 5 Dec 2014
Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma 7:27
Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma
Craig Moskowitz • 5 Dec 2014
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma 1:39
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
Jeffrey Matous • 6 Dec 2014
Phase Ib dose escalation trial of SAR650984 improves outcomes in relapsed or refractory myeloma 9:21
Phase Ib dose escalation trial of SAR650984 improves outcomes in relapsed or refractory myeloma
Thomas Martin • 5 Dec 2014
Phase III study shows carfilzomib is an effective addition to standard myeloma therapy 5:42
Phase III study shows carfilzomib is an effective addition to standard myeloma therapy
Andrew Stewart • 5 Dec 2013
MRD in myeloma and proteasome inhibition in amyloidosis 3:06
MRD in myeloma and proteasome inhibition in amyloidosis
Rafael Fonseca • 5 Sep 2014
The content of VJHemOnc is intended for healthcare professionals